Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-523 Food Effect Study in Healthy Participants
NCT07348133Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Dec 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sovleplenib in immune thrombocytopenia (ITP), sponsored by HUTCHMED. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration, Area Under the Concentration-Time Curve from Time Zero Extrapolated to Infinity and 3 more. Started Dec 2025; status: completed.
02
Drugs
sovleplenib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07348133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348133.